After five years of unprecedented momentum, the ADC field now finds itself at an interesting inflection point. With more programs in development and greater industry prioritization than ever before, ...

Deal-hungry Ipsen is at it again, pledging just over $1 billion for rights to an antibody-drug conjugate (ADC) for cancer developed by China's Simcere Zaiming, that is due to start clinical testing ...

Synaffix’s glycan-based antibody–drug conjugate technology is experiencing strong demand, based on its potential to improve safety and efficacy of cancer therapies without genetic engineering.